目的:探讨弥漫大B细胞淋巴瘤(Diffuse Large B-Cell Lymphoma,DLBCL)中1号染色体基因表达情况。方法:采用激光显微切割技术分离临床DLBCL病人淋巴结标本中的淋巴细胞,提取淋巴细胞的mRNA并与表达谱芯片杂交,通过信号扫描、处理后获得表...目的:探讨弥漫大B细胞淋巴瘤(Diffuse Large B-Cell Lymphoma,DLBCL)中1号染色体基因表达情况。方法:采用激光显微切割技术分离临床DLBCL病人淋巴结标本中的淋巴细胞,提取淋巴细胞的mRNA并与表达谱芯片杂交,通过信号扫描、处理后获得表达基因杂交信号强度。每基因设11-20对探针。杂交信号与错配探针对比,扣除背景值后,使用Wilcoxon符号秩和检验选取与错配杂交信号有显著差异的基因作为分析结果(P=0.05)。然后随机选取四个检测到的基因,使用PCR方法检验基因芯片结果的可靠性。结果:成功地从快速冷冻保存的DLBCL标本中提取RNA。使用表达谱芯片进行研究,发现了共316条1号染色体编码的基因在DLBCL细胞中表达。根据胞内定位,基因功能和基因所属的代谢通路三种分类方法对所得基因进行分类分析。基因表达密度分析显示DLBCL中1号染色体上的基因表达情况与编码基因分布情况存在统计学差异。结论:使用表达谱芯片研究了DLBCL中1号染色体上的基因表达情况。展开更多
The aim of this study was to evaluate the safety and efficiency of a novel,oncolytic adenovirus mutant M1 administered in conjunction with immunosuppressive agents.Animal models were established by administering purif...The aim of this study was to evaluate the safety and efficiency of a novel,oncolytic adenovirus mutant M1 administered in conjunction with immunosuppressive agents.Animal models were established by administering purified M1 either intravenously or retroperitoneally.At different time points,blood samples were taken from the mice for testing of liver and renal function.Microscopic examination of the liver was performed to observe pathological changes.Immunohistochemical analyses were used to evaluate the expression of the adenovirus in the liver.Lymphocyte recruitment to the liver and the activation of adenovirus specific T cells were also analyzed.No signs of general toxicity were observed,but transient increases in ALT and Scr were observed following the administration of M1.Microscopic examination revealed a mild inflammatory response in the liver.Compared to intravenous injection,higher expression levels of adenoviral proteins were observed after retroperitoneal injection.Combined treatment with cyclosporine A resolved the liver and kidney dysfunction and increased the concentration of the adenovirus in the liver.The use of the novel oncolytic adenovirus mutant M1 in vivo is safe,and the combined administration of M1 with immunosuppressive agents was able to enhance the effectiveness and safety profile of M1.展开更多
文摘目的:探讨健康人外周血中tyrosine kinase with Ig-like loops and epidermal growth factor homology domains-2(Tie2)-expressing monocytes(TEMs)的存在以及其所占的比例。方法:采用红细胞裂解法获得人外周血白细胞,Phycoerythrin(PE)标记抗人Cluster of Differentiation 14(CD14)抗体及Tie2抗体分别孵育所获取的白细胞,流式细胞仪检测CD14阳性细胞及Tie2阳性细胞的比例。结果:外周血白细胞中,CD14阳性率为2.04%,Tie2阳性率为0.71%。CD14阳性细胞中,Tie2阳性率为13.07%。结论:TEMs在健康人外周血白细胞中存在,并且主要分布于CD14阳性的单核细胞群。
文摘目的:探讨弥漫大B细胞淋巴瘤(Diffuse Large B-Cell Lymphoma,DLBCL)中1号染色体基因表达情况。方法:采用激光显微切割技术分离临床DLBCL病人淋巴结标本中的淋巴细胞,提取淋巴细胞的mRNA并与表达谱芯片杂交,通过信号扫描、处理后获得表达基因杂交信号强度。每基因设11-20对探针。杂交信号与错配探针对比,扣除背景值后,使用Wilcoxon符号秩和检验选取与错配杂交信号有显著差异的基因作为分析结果(P=0.05)。然后随机选取四个检测到的基因,使用PCR方法检验基因芯片结果的可靠性。结果:成功地从快速冷冻保存的DLBCL标本中提取RNA。使用表达谱芯片进行研究,发现了共316条1号染色体编码的基因在DLBCL细胞中表达。根据胞内定位,基因功能和基因所属的代谢通路三种分类方法对所得基因进行分类分析。基因表达密度分析显示DLBCL中1号染色体上的基因表达情况与编码基因分布情况存在统计学差异。结论:使用表达谱芯片研究了DLBCL中1号染色体上的基因表达情况。
基金supported by National Natural Science Youth Foundation of China (No. 81001049)
文摘The aim of this study was to evaluate the safety and efficiency of a novel,oncolytic adenovirus mutant M1 administered in conjunction with immunosuppressive agents.Animal models were established by administering purified M1 either intravenously or retroperitoneally.At different time points,blood samples were taken from the mice for testing of liver and renal function.Microscopic examination of the liver was performed to observe pathological changes.Immunohistochemical analyses were used to evaluate the expression of the adenovirus in the liver.Lymphocyte recruitment to the liver and the activation of adenovirus specific T cells were also analyzed.No signs of general toxicity were observed,but transient increases in ALT and Scr were observed following the administration of M1.Microscopic examination revealed a mild inflammatory response in the liver.Compared to intravenous injection,higher expression levels of adenoviral proteins were observed after retroperitoneal injection.Combined treatment with cyclosporine A resolved the liver and kidney dysfunction and increased the concentration of the adenovirus in the liver.The use of the novel oncolytic adenovirus mutant M1 in vivo is safe,and the combined administration of M1 with immunosuppressive agents was able to enhance the effectiveness and safety profile of M1.
